At a glance
ClinicalIndex Comparison RecordN/ACompleted· 278 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis Patients at 6, 12 and 18 Months
In Brief
An observational study for RheumatoId Arthritis. Completed, enrolled 278 participants across 1 site.
Detailed Summary
Patients with rheumatoid arthritis (RA) with positive antibodies against carbamylated proteins (anti-CarP) have a more severe clinical course. The primary objective of this study in adult subject with RA is as follows: To explore the clinical differences in activity indexes (Disease Activity Score of 28 joints with Erythro Sedimentaion Rate (DAS28-ESR)) at 6, 12 and 18 months of follow up according the anti-CarP antibodies status.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoId Arthritis
CountriesMexico
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedNov 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartJun 1, 2016
Primary CompletionNov 26, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.7 years ago